Genetic Metabolic Diseases Get Their Own US FDA Advisory Committee

 
• By Sue Sutter

In a first for rare diseases, a new standing committee will provide advice and recommendations on technical, scientific and policy issues related to medical products for genetic metabolic diseases.  

Welcome sign
CDER is hanging out the welcome banner for its newest advisory committee. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers